BUZZ-欧洲监管机构将重新评估对肌肉失调药物的意见，PTC Therapeutics 上涨

Reuters05-21

((自动化翻译由路透提供，请见免责声明 ))

5月20日 - ** 制药商PTC Therapeutics 股价上涨20.4%至39.86美元

** 该公司称，欧盟执委会$(EC)$ 已决定不采纳欧洲卫生监管机构顾问小组对该公司肌肉失调药物 Translarna 的负面意见。

** 称欧盟执委会已将该意见退回卫生监管机构的顾问小组重新评估

** 因此，Translarna仍可供欧洲患者使用 - PTCT

** 欧盟执委会已要求顾问小组 "在修订意见中进一步考虑全部证据，包括来自患者登记处的数据和真实世界的证据"。

** 我们认为欧盟执委会的决定很可能反映了医生和患者拥护者的强烈反弹，他们没有其他治疗选择，并认为 Translarna 是一种安全有效的治疗方法......"威廉-布莱尔公司分析师萨米-科尔文说

** 包括盘中走势在内，该股今年累计上涨 44.2

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2437483210?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-05-21 01:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2437483210","market":"us","top_or_hot":-1,"title":"BUZZ-欧洲监管机构将重新评估对肌肉失调药物的意见，PTC Therapeutics 上涨","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    5月20日 - ** 制药商PTC <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>   股价上涨20.4%至39.86美元</p><p>** 该公司称，欧盟执委会<a href=\"https://laohu8.com/S/EC\">$(EC)$</a> 已决定不采纳欧洲卫生监管机构顾问小组对该公司肌肉失调药物 Translarna 的负面意见。</p><p>** 称欧盟执委会已将该意见退回卫生监管机构的顾问小组重新评估</p><p>** 因此，Translarna仍可供欧洲患者使用 - PTCT</p><p>** 欧盟执委会已要求顾问小组 \"在修订意见中进一步考虑全部证据，包括来自患者登记处的数据和真实世界的证据\"。</p><p>** 我们认为欧盟执委会的决定很可能反映了医生和患者拥护者的强烈反弹，他们没有其他治疗选择，并认为 Translarna 是一种安全有效的治疗方法......\"威廉-布莱尔公司分析师萨米-科尔文说</p><p>** 包括盘中走势在内，该股今年累计上涨 44.2 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-欧洲监管机构将重新评估对肌肉失调药物的意见，PTC Therapeutics 上涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-欧洲监管机构将重新评估对肌肉失调药物的意见，PTC Therapeutics 上涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-21 01:47 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    5月20日 - ** 制药商PTC Therapeutics   股价上涨20.4%至39.86美元** 该公司称，欧盟执委会$(EC)$ 已决定不采纳欧洲卫生监管机构顾问小组对该公司肌肉失调药物 Translarna 的负面意见。** 称欧盟执委会已将该意见退回卫生监管机构的顾问小组重新评估** 因此，Translarna仍可供欧洲患者使用 -...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1923623000.USD","symbol_name":"Natixis Thematics AI & Robotics Fund R/A USD","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2437483210","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2437483210","pubTimestamp":1716227279,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"    5月20日 - ** 制药商PTC Therapeutics   股价上涨20.4%至39.86美元** 该公司称，欧盟执委会 已决定不采纳欧洲卫生监管机构顾问小组对该公司肌肉失调药物 Translarna 的负面意见。** 称欧盟执委会已将该意见退回卫生监管机构的顾问小组重新评估** 因此，Translarna仍可供欧洲患者使用 - PTCT** 欧盟执委会已要求顾问小组 \"在修订意见中进一步考虑全部证据，包括来自患者登记处的数据和真实世界的证据\"。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","BK4585":"ETF&股票定投概念","BK4576":"AR","LENZ":"Therapeutics","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","PTC":"PTC Inc.","BK4588":"碎股","BUZZ":"VanEck Social Sentiment ETF","PTCT":"PTC Therapeutics Inc.","BK4139":"生物科技","BK4023":"应用软件","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4554":"元宇宙及AR概念"},"translate_title":"BUZZ-PTC Therapeutics rises as European regulators set to reassess opinions on muscle imbalance drug","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BUZZ":1,"LENZ":1,"PTC":1,"PTCT":0.9},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    5月20日 - ** 制药商PTC Therapeutics   股价上涨20.4%至39.86美元** 该公司称，欧盟执委会$(EC)$ 已决定不采纳欧洲卫生监管机构顾问小组对该公司肌肉失调药物 Translarna 的负面意见。** 称欧盟执委会已将该意见退回卫生监管机构的顾问小组重新评估** 因此，Translarna仍可供欧洲患者使用 - PTCT** 欧盟执委会已要求顾问小组 \"在修订意见中进一步考虑全部证据，包括来自患者登记处的数据和真实世界的证据\"。** 我们认为欧盟执委会的决定很可能反映了医生和患者拥护者的强烈反弹，他们没有其他治疗选择，并认为 Translarna 是一种安全有效的治疗方法......\"威廉-布莱尔公司分析师萨米-科尔文说** 包括盘中走势在内，该股今年累计上涨 44.2","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2437483210"}